Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-05
2006-09-05
Celsa, Bennett (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800
Reexamination Certificate
active
07101853
ABSTRACT:
Methods for treating or preventing gastritis or gastric injury are disclosed, comprising administering a therapeutically effective amount of an amylin or an amylin agonist. Methods are also disclosed for the treatment of pain, fever, inflammation, arthritis, hypercoagulability, or other conditions for which a non-steroidal anti-inflammatory drug would be indicated, comprising administering an amylin or amylin agonist in conjunction with administering a therapeutically effective amount of a non-steroidal anti-inflammatory agent. Pharmaceutical compositions comprising an amylin or amylin agonist and a non-steroidal anti-inflammatory drug are also disclosed.
REFERENCES:
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5795861 (1998-08-01), Kolterman et al.
patent: 6114304 (2000-09-01), Kolterman et al.
patent: WO 95/07098 (1995-03-01), None
Beaumont, et al., “High Affinity Amylin Binding Sites in Rat Brain,”Molecular Pharmacology, 44:493-497 (1993).
Gray, et al., “A Role for Calcitonin Gene-Related Peptide in Protection Against Gastric Ulceration,”Annals of Surgery, 219(1):58-64 (1994)—Abstract.
Hartter, et al., “Basal and Stimulated Plasma Levels of Pancreatic Amylin Indicate its Co-secretion with Insulin in Humans,”Diabetologia, 34:52-54 (1991).
Maggi, et al., “Anti-ulcer Activity of Calcitonin Gene-Related Peptide in Rats,”Gen. Pharmacol., 18(1):33-34 (1987)—Abstract.
Miller, et al., “Calcitonin Gene-Related Peptide (CGRP) Upregulates the Restitution of Rat Gastric Mucosa In Vitro,”Journal of Surgical Research, 58(4):421-424 (1995)—Abstract.
Pittner, “Lack of Effect of Calcitonin Gene-Related Peptide and Amylin on Major Markers of Glucose Metabolism in Hepatocytes,”European Journal of Pharmacology, 325:189-197 (1997).
Tache, “Inhibition of Gastric Acid Secretion and Ulcers and by Calciton Gene-Related Peptide,”Ann. N.Y. Acad. Sci., 657:240-247 (1992).
Young, et al., “Preclinical Pharmacology of Pramlintide in the Rat: Comparisons With Human and Rat Amylin,”Drug Development Research, 37:231-248 (1996).
Young, et al., “8-37hCGRP, an Amylin Receptor Antagonist, Enhances the Insulin Response and Perturbs the Glucose Response to Infused Arginine in Anesthetized Rats,”Molecular and Cellular Endocrinology, 84:R1-R5 (1992).
Guidobono, et al., “Effect of amylin on gastric acid secretion and gastric ulcers in the rat,”Fund. Clinical&Pharm., Abstract 3rd joint meeting of the Societa Italiana di Farmacologia and the Association Francaise des Pharmacologistes; Capri, Italy May 23-26, 1996.
Database WPI, Section Ch, Week 199546, Derwent Publications Ltd., London, GB; AN 1995-351860 XP002163755 (1994).
Gedulin, et al., “Amylin inhibits pentagastrin-simulated gastric acid secretion and protects against ethanol-induced gastric mucosal damage in rats,”Diabetologia, 40(Supp 1): Jun. 1997.
Kolterman et al., “Effect of 14 Days' Subcutaneous Administration of the Human Amylin Analogue, Pramlintide (AC137), on an Intravenous Insulin Challenge and Response to a Standard Liquid Meal in Patients with IDDM,”Diabetologia, 39:492-499 (1996).
Beynon Gareth Wyn
Gedulin Bronislava
Young Andrew A.
Amylin Pharmaceuticals Inc.
Arnold & Porter LLP
Celsa Bennett
LandOfFree
Method for treating or preventing gastritis using amylin or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating or preventing gastritis using amylin or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating or preventing gastritis using amylin or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3604239